Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-centre, Open Single-arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will be Evaluated in Patients With Amyotrophic Lateral Sclerosis

Trial Profile

A Single-centre, Open Single-arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will be Evaluated in Patients With Amyotrophic Lateral Sclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs Dextran sulfate (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors TikoMed
  • Most Recent Events

    • 02 Nov 2018 According to a TikoMed media release, first patient has been treated in the trial.
    • 14 Aug 2018 According to a TikoMed media release, this study is performed at and in collaboration with Sahlgrenska University Hospital, Gothenburg, Sweden. Assoc. Professor Lennart Persson, an expert in ALS, will be principal investigator.
    • 14 Aug 2018 Status changed from not yet recruiting to recruiting, according to a TikoMed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top